{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53460"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53460","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Serine/theronine kinase 25 is a tumor suppressor that impairs mechanistic target of rapamycin complex 1 activity","abstract":"The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism. Aberrant hyperactivation of mTORC1 has been associated with various pathologies, including cancer. Although mTORC1 signaling has been extensively studied, the upstream mechanisms that restrain mTORC1 activity are not fully defined. Here, we identify Serine/Threonine Kinase 25 (STK25), a Ste20 family kinase previously linked to Hippo signaling, as a negative regulator of mTORC1. Loss of STK25 increases mTORC1 activity in vitro and in vivo. Mechanistically, STK25 suppresses mTORC1 independently of both canonical AKT1-TSC1/2-mediated regulation and Hippo signaling crosstalk regulation. Functionally, STK25 depletion is sufficient to drive late-onset tumorigenesis in conditional knockout mice and results in concurrent activation of mTORC1 signaling and YAP, a Hippo pathway effector that drives transcription via association with transcription factors TEAD1-4. Consistent with this dual pathway activation, primary mouse tumor cells exhibit increased sensitivity to the mTORC1 inhibitor rapamycin and TEAD inhibitor VT104, resulting in reduced viability. Together, these findings establish STK25 as a dual upstream regulator of the Hippo and mTORC1 pathways and suggest that STK25-deficient tumors may be exceptionally vulnerable to combined mTORC1 and TEAD inhibition.","abstract_html":"The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism. Aberrant hyperactivation of mTORC1 has been associated with various pathologies, including cancer. Although mTORC1 signaling has been extensively studied, the upstream mechanisms that restrain mTORC1 activity are not fully defined. Here, we identify Serine/Threonine Kinase 25 (STK25), a Ste20 family kinase previously linked to Hippo signaling, as a negative regulator of mTORC1. Loss of STK25 increases mTORC1 activity in vitro and in vivo. Mechanistically, STK25 suppresses mTORC1 independently of both canonical AKT1-TSC1/2-mediated regulation and Hippo signaling crosstalk regulation. Functionally, STK25 depletion is sufficient to drive late-onset tumorigenesis in conditional knockout mice and results in concurrent activation of mTORC1 signaling and YAP, a Hippo pathway effector that drives transcription via association with transcription factors TEAD1-4. Consistent with this dual pathway activation, primary mouse tumor cells exhibit increased sensitivity to the mTORC1 inhibitor rapamycin and TEAD inhibitor VT104, resulting in reduced viability. Together, these findings establish STK25 as a dual upstream regulator of the Hippo and mTORC1 pathways and suggest that STK25-deficient tumors may be exceptionally vulnerable to combined mTORC1 and TEAD inhibition.","abstract_has_math":false,"creators":["Ho, Rachel Xi-Yeen"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Molecular and Translational Medicine","degree_department":null,"school":null,"contributors":[],"advisors":["Ganem, Neil J."],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-19T02:42:12Z","subjects":["Molecular biology","Cellular biology","Oncology","Cancer Biology","Hippo signaling","Mouse tumor model","mTORC1 signaling","STK25","Tumor suppressor"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-8346-2328"],"render_values":[{"text":"0000-0002-8346-2328","href":"https://orcid.org/0000-0002-8346-2328","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/53460","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53460","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53460","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Ganem, Neil J."]},{"key":"dc:creator","label":"Author","values":["Ho, Rachel Xi-Yeen"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-8346-2328"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-09-14T18:49:52Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2027-09-11T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-09-11T22:15:43Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular and Translational Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Molecular biology","Cellular biology","Oncology","Cancer Biology","Hippo signaling","Mouse tumor model","mTORC1 signaling","STK25","Tumor suppressor"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53460"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism. Aberrant hyperactivation of mTORC1 has been associated with various pathologies, including cancer. Although mTORC1 signaling has been extensively studied, the upstream mechanisms that restrain mTORC1 activity are not fully defined. Here, we identify Serine/Threonine Kinase 25 (STK25), a Ste20 family kinase previously linked to Hippo signaling, as a negative regulator of mTORC1. Loss of STK25 increases mTORC1 activity in vitro and in vivo. Mechanistically, STK25 suppresses mTORC1 independently of both canonical AKT1-TSC1/2-mediated regulation and Hippo signaling crosstalk regulation. Functionally, STK25 depletion is sufficient to drive late-onset tumorigenesis in conditional knockout mice and results in concurrent activation of mTORC1 signaling and YAP, a Hippo pathway effector that drives transcription via association with transcription factors TEAD1-4. Consistent with this dual pathway activation, primary mouse tumor cells exhibit increased sensitivity to the mTORC1 inhibitor rapamycin and TEAD inhibitor VT104, resulting in reduced viability. Together, these findings establish STK25 as a dual upstream regulator of the Hippo and mTORC1 pathways and suggest that STK25-deficient tumors may be exceptionally vulnerable to combined mTORC1 and TEAD inhibition."]},{"key":"dc:title","label":"Title","values":["Serine/theronine kinase 25 is a tumor suppressor that impairs mechanistic target of rapamycin complex 1 activity"]}]}],"canonical_facts":{"dc:contributor.advisor":["Ganem, Neil J."],"dc:creator":["Ho, Rachel Xi-Yeen"],"dc:date.accessioned":["2026-09-14T18:49:52Z"],"dc:date.embargo":["2027-09-11T00:00:00Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-09-11T22:15:43Z"],"dc:description":["2026"],"dc:description.abstract":["The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism. Aberrant hyperactivation of mTORC1 has been associated with various pathologies, including cancer. Although mTORC1 signaling has been extensively studied, the upstream mechanisms that restrain mTORC1 activity are not fully defined. Here, we identify Serine/Threonine Kinase 25 (STK25), a Ste20 family kinase previously linked to Hippo signaling, as a negative regulator of mTORC1. Loss of STK25 increases mTORC1 activity in vitro and in vivo. Mechanistically, STK25 suppresses mTORC1 independently of both canonical AKT1-TSC1/2-mediated regulation and Hippo signaling crosstalk regulation. Functionally, STK25 depletion is sufficient to drive late-onset tumorigenesis in conditional knockout mice and results in concurrent activation of mTORC1 signaling and YAP, a Hippo pathway effector that drives transcription via association with transcription factors TEAD1-4. Consistent with this dual pathway activation, primary mouse tumor cells exhibit increased sensitivity to the mTORC1 inhibitor rapamycin and TEAD inhibitor VT104, resulting in reduced viability. Together, these findings establish STK25 as a dual upstream regulator of the Hippo and mTORC1 pathways and suggest that STK25-deficient tumors may be exceptionally vulnerable to combined mTORC1 and TEAD inhibition."],"dc:identifier.orcid":["0000-0002-8346-2328"],"dc:identifier.uri":["https://hdl.handle.net/2144/53460"],"dc:language.iso":["en_US"],"dc:subject":["Molecular biology","Cellular biology","Oncology","Cancer Biology","Hippo signaling","Mouse tumor model","mTORC1 signaling","STK25","Tumor suppressor"],"dc:title":["Serine/theronine kinase 25 is a tumor suppressor that impairs mechanistic target of rapamycin complex 1 activity"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Molecular and Translational Medicine"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:42:12Z"}